← Back to patent-cliff list
Amdizalisib
Tier C — Watch / tradeAmdizalisib
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
-
Type
Targets：PI3Kδ
Indications (approved)：Lymphoma, Marginal zone B-cell lymphoma, Follicular lymphoma, Non-Hodgkin lymphoma, B-cell lymphoma
Regional status
US
Phase I
2019-08-26
EU
Discontinued
2019-08-26
China
Phase II
2021-04-15
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Amdizalisib?
Approved indications include: Lymphoma, Marginal zone B-cell lymphoma, Follicular lymphoma, Non-Hodgkin lymphoma, B-cell lymphoma.
When does the Amdizalisib patent expire?
No public expiry year is available for Amdizalisib yet; this page updates once verified.
How do I get a quote for Amdizalisib intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-21